Wire · opportunities
Regeneron Pharma's Pasatru receives US FDA approval to reduce formation of heterotopic ...
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 22 August 2026 · Fusion42 review
Regeneron Pharmaceuticals received US FDA approval for Pasatru, a monoclonal antibody treatment to reduce new heterotopic ossification lesions and flare-ups in adults with fibrodysplasia ossificans progressiva (FOP), an ultra-rare genetic disorder causing progressive bone formation in connective tissues. The approval is based on positive phase 3 OPTIMA trial data showing a significant reduction in new lesions and flare-ups.
This Wire brief sits within Fusion42's coverage of Biotech, and 7 sources have reported it between 19 Aug 2026 and 22 Aug 2026.
◆ ◆ The Wire takeaway
You now have a clear market entry point in treating fibrodysplasia ossificans progressiva with Pasatru getting US FDA approval. Prepare to position your product or partnership efforts around treatments that target rare genetic disorders with monoclonal antibodies.
◆ Coverage
7 sources · first reported 19 Aug 2026 · latest 22 Aug 2026
◆ Topics